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Encephalitis is a clinical syndrome commonly caused 
by emerging pathogens, which are not under surveillance 
in Australia. We reviewed rates of hospitalization for pa-
tients with encephalitis in Australia’s most populous state, 
New South Wales, from January 1990 through December 
2007. Encephalitis was the primary discharge diagnosis for 
5,926 hospital admissions; average annual hospitalization 
rate was 5.2/100,000 population. The most commonly iden-
tified pathogen was herpes simplex virus (n = 763, 12.9%). 
Toxoplasma encephalitis and subacute sclerosing panen-
cephalitis  showed  notable  declines. The  average  annual 
encephalitis  case-fatality  rate  (4.6%)  and  the  proportion 
of patients hospitalized with encephalitis with no identified 
pathogen (69.8%, range 61.5%–78.7%) were stable during 
the study period. The nonnotifiable status of encephalitis 
in Australia and the high proportion of this disease with no 
known  etiology  may  conceal  emergence  of  novel  patho-
gens. Unexplained encephalitis should be investigated, and 
encephalitis hospitalizations should be subject to statutory 
notification in Australia.
M
any novel infectious diseases have been reported 
since 1940; most have been zoonoses originating 
from wildlife (1). Several novel zoonotic viruses, includ-
ing Hendra virus, Australian bat lyssavirus, and Nipah 
virus,  have  resulted  in  encephalitic  illness  in  humans 
(2–4). Australia has witnessed the emergence of several 
zoonotic and arboviral pathogens associated with enceph-
alitis; these pathogens have been either novel pathogens 
or pathogens appearing in new geographic locations and 
include Hendra virus, Murray Valley encephalitis virus, 
Australian bat lyssavirus, and Kunjin and Japanese en-
cephalitis viruses (5–7). The appearance of these emerg-
ing pathogens that can result in encephalitis raises ques-
tions about the etiology of encephalitis in the Australian 
population  and  about  the  adequacy  of  surveillance  for 
novel pathogens.
Encephalitis is an inflammatory process in the brain 
parenchyma  and  is  associated  with  clinical  evidence  of 
brain dysfunction (8). An infectious etiology of encepha-
litis is usually suspected in a patient with fever, headache, 
and signs of diffuse brain dysfunction, often with focal 
neurologic signs (9,10). Encephalitis generally results in a 
serious illness requiring hospitalization. Severe encepha-
litic illness can lead to death, and survivors frequently ex-
perience ongoing neurologic sequelae (9,10).
Presumably, the most common etiologies of encephali-
tis are infectious (11), and viral pathogens account for most 
diagnosed cases. In developed countries, the most common-
ly identified pathogens associated with acute encephalitis 
are the herpes viruses (9,12–15). Herpes simplex encepha-
litis is believed to account for 10%–20% of cases (12), but 
pathogen identification is not always possible (16).
Several countries have conducted large epidemiologic 
studies to assess the impact of disease caused by encepha-
litis and to determine its etiology. Davison et al. reviewed 
UK hospital records for a 9-year period (1989–1998) and 
found that the hospitalization rate for viral encephalitis in 
UK hospitals was 1.5 cases per 100,000 population; 60% 
of cases were recorded as unidentified viral infection (17). 
During the study period in the United Kingdom, 419 deaths 
were attributed to viral encephalitis (overall case-fatality 
rate 6.5/100 cases), but an etiologic organism was iden-
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tified for only 50% of these deaths (17). A smaller pro-
spective study conducted in Finland for a 25-year period 
(1967–1991) found no etiology for encephalitis in 49% of 
322 patients hospitalized with this illness (18).
Khetsuriani et al. analyzed national data for the Unit-
ed States over a similar period (1988–1997) to estimate 
the impact of both viral and nonviral encephalitis hos-
pitalizations (11). This study found that the hospitaliza-
tion rate for encephalitis in the United States was 7.3 per 
100,000 population, and no specific etiology was identi-
fied in 59.5% of cases. During the study period, a case-
fatality rate of 7.4 per 100 cases was recorded. For those 
persons admitted with encephalitis for which an etiology 
was identified, most specified a viral etiology (11). Also 
in the United States, the California Encephalitis Study, a 
large prospective study, found that 63% of hospitalized 
patients with encephalitis from 1998 through 2005 had 
encephalitis of unknown etiology, despite extensive labo-
ratory testing (19). In another US study of persons whose 
deaths were associated with encephalitis, 81.5%–86.2% 
of the deaths resulted from encephalitis with an unknown 
etiology (20).
In Australia, encephalitis, as a syndrome, is not a no-
tifiable disease, and data about trends or even clusters of 
this disease are not routinely collected. Only laboratory-
confirmed encephalitis cases due to certain pathogens (e.g., 
Murray  Valley  encephalitis  virus,  Japanese  encephalitis 
virus, or Australian bat lyssavirus) are notifiable to public 
health units; thus, the occurrence of encephalitis is not well 
documented.
A single, small study conducted in Australia’s tropical 
Northern Territory found that 18 (53%) of 34 encephali-
tis patients admitted to the Royal Darwin Hospital during 
a 5-year period (1992–1996) had encephalitis with unex-
plained etiology (21). This level of unknown pathogen eti-
ology suggests that Australia has a similar rate of pathogen 
identification as that reported in the overseas studies. How-
ever, the relative importance of different pathogens may 
differ because Australia has unique pathogens such as Mur-
ray Valley encephalitis virus, Hendra virus, and Australian 
bat lyssavirus) (5). 
In this study, we examine the impact of hospitaliza-
tions  due  to  encephalitis  in  New  South  Wales  (NSW), 
Australia’s most populous state. We also describe trends 
in pathogen identification in patients hospitalized with en-
cephalitis over the 18-year period 1990–2007.
Methods
Data Sources
Data on hospital discharges, deaths, and population 
for NSW were obtained for 1990–2007 from the Health 
Outcomes  and  Information  Statistical  Toolkit,  a  collec-
tion  of  databases  maintained  by  the  Epidemiology  and 
Surveillance Branch of the NSW Department of Health. 
The datasets used were from the Inpatient Statistics Col-
lection library. Encephalitis-associated hospital stays were 
extracted for the period for patients for whom data were 
complete by using International Classification of Diseases, 
9th revision, Clinical Modification codes (ICD-9-CM, Jan 
1990–Jun 1998) and International Classification of Diseas-
es,  10th  revision,  Australian  Modification  (ICD-10-AM, 
July 1998–Dec 2007).
Data for encephalitis-associated deaths in NSW were 
extracted from the Australian Bureau of Statistics death 
library by using ICD-9 (1990–1997) and ICD-10 (1998–
2006) codes. Data for deaths occurring in 2007 were un-
available  at  the  time  of  extraction.  Population  statistics 
from  the  Australian  Bureau  of  Statistics  were  accessed 
through the Health Outcomes and Information Statistical 
Toolkit for the same period.
Definitions
An encephalitis-associated hospital stay was defined 
as a hospitalization for which the primary discharge di-
agnosis was an ICD-9-CM or ICD-10-AM code for acute 
encephalitis. Relevant ICD-9-CM and ICD-10-AM codes 
were obtained by searching the alphabetical list of ICD 
codes for all codes that include the term enceph, but ex-
cluding  nonencephalitis  conditions  (e.g.,  anencephaly) 
and including rabies. Additionally, 2 ICD-9-CM codes 
used for encephalitis-related conditions before July 1998 
did not include the prefix enceph-, unlike nomenclatures 
used  in  ICD-10-AM  encephalitis  codes.  One  of  these 
ICD-9-CM codes was 49.8, defined as other non–arthro-
pod-borne viral diseases of central nervous system –other 
specified non–arthropod-borne viral diseases of the cen-
tral nervous system. The other code was 49.9, defined 
as  other  non–arthropod-borne  viral  diseases  of  central 
nervous system –unspecified non–arthropod-borne viral 
diseases of the central nervous system. The use of these 
codes was found by comparing data extracted for 1998 
and 1999. For these 2 years, coding was performed in both   
ICD-9-CM and ICD-10-AM, and data were then com-
pared to identify the additional codes.
The  Table  shows  the  ICD-9-CM  and  ICD-10-AM 
encephalitis-associated conditions with codes used for en-
cephalitis hospitalizations during 1990–2007. These codes 
were further classified by investigators into encephalitis 
with known pathogens or unknown pathogens (Table).
Data Analysis and Ethics
Encephalitis-associated  hospitalizations  were  ana-
lyzed by using SAS version 8.0 (SAS Institute, Inc., Cary, 
NC, USA) by etiologic category, year, age, gender, and 
hospital  location.  Hospitalization  rates  and  death  rates 
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were  calculated  by  using  annualized  population  esti-
mates from the Australian Bureau of Statistics. Negative 
binomial regression was used to analyze trends for hos-
pitalization rates of all encephalitis hospitalizations and 
for those caused by known and unknown pathogens. The 
regression was repeated with adjustment for age groups 
over time by using log of the population as an offset and 
age as a categorical covariate. Trends were represented 
as annual percentage changes in rates. Ethical clearance 
was given by Hunter New England Population Health and 
by the Australian National University Human Research   
Ethics Committee.
Results
Encephalitis Hospitalizations
From  January  1990  through  December  2007,  en-
cephalitis accounted for 5,926 hospitalizations in NSW. 
The average number of hospitalizations per year was 329 
(range 281–393). The most frequently identified etiology 
of encephalitis was herpes simplex virus infection, which 
accounted for 763 admissions (12.9%) (Table). Varicella 
encephalitis  (226  admissions  or  3.8%)  and  Toxoplasma 
meningoencephalitis (221 admissions or 3.7%) were also 
common known etiologies. The etiology of 4,126 admis-
sions (69.6% of total admissions) was unknown.
The  average  annual  rate  of  encephalitis  hospital-
ization  was  5.2  per  100,000  population  (range  4.2–6.7)   
(Figure 1). The annual rate for total encephalitis cases was 
higher for men (average rate 5.7/100,000) than for women 
(4.7/100,000).
The  case-fatality  rate  for  encephalitis  during  1990–
2006 was 4.6/100 cases. Figure 2 shows the average rate 
of hospitalization for patients with encephalitis by 10-year 
age groups during 1990–2007. The highest rates of admis-
sion occurred for age groups 0–9 years and >60 years.
Pathogen Identification
The rate of encephalitis hospitalizations declined for 
admissions of patients with encephalitis with both known 
and unknown etiologies (Figure 1). A negative binomial 
regression model showed a statistically significant decline 
of 1.4% per year (p = 0.0003, 95% confidence interval [CI] 
0.7%–2.2%) for total encephalitis admissions during 1990–
2007. This trend was similar for cases of encephalitis with 
unknown etiologies (decline of 1.4% per year, p = 0.0002, 
95% CI 0.7%–2.2%) and for encephalitis cases with known 
etiologies, although the effect was not statistically signifi-
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Table. Encephalitis-associated conditions with ICD-9-CM and ICD-10-AM codes most frequently used for primary encephalitis 
discharge diagnoses, New South Wales, Australia, 1990–2007* 
Primary discharge diagnosis ICD code (ICD-9; ICD-10) 
No. hospitalizations 
(% of total) 
All hospitalizations  5,926 (100) 
Known pathogens  1,800 (30.6) 
Herpes viral encephalitis (54.3; B00.4)  763 (12.9) 
Varicella encephalitis (52.0; B01.1)  226 (3.8) 
Toxoplasma meningoencephalitis (130.0; B58.2 )  221(3.7) 
Acute disseminated encephalitis (G04.0 in ICD-10)  136 (2.3) 
Zoster encephalitis (B02.0 in ICD-10)  105 (1.8) 
Subacute sclerosing panencephalitis (46.2; A81.1)  79 (1.3) 
Other specified non–arthropod-borne viral diseases of the central nervous system (49.8; A85.8)  71 (1.2) 
Enteroviral encephalitis (A85.0 in ICD-10)  49 (0.8) 
Listerial meningitis and meningoencephalitis (A32.1 in ICD 10)  28 (0.5) 
Encephalitis, myelitis, and encephalomyelitis –postinfectious encephalitis (323.6 in ICD-9)  18 (0.3) 
Measles encephalitis (55.0 in ICD 9)  15 (0.3) 
Encephalitis, myelitis, and encephalomyelitis –encephalitis in viral diseases classified elsewhere  
(323.0 in ICD 9) 
10 (0.2) 
Rubella with neurologic complications –encephalomyelitis due to rubella (56.01 in ICD-9)  8 (0.1) 
Meningococcal infection –meningococcal encephalitis (36.1 in ICD-9)  7 (0.1) 
Viral encephalitis transmitted by other and unspecified arthropods (64 in ICD-9)  7 (0.1) 
Bacterial meningoencephalitis and meningomyelitis, not elsewhere classified (G04.2 in ICD-10)  7 (0.1) 
Mumps –mumps encephalitis (72.2 in ICD-9)  6 (0.1) 
Other known pathogen codes (24 codes)  44 (0.7) 
Unknown pathogens  4,126 (69.6) 
Unspecified non–arthropod-borne viral diseases of the central nervous system or unspecified viral 
encephalitis (49.9; A86)  2,218 (37.4) 
Encephalitis, myelitis, and encephalomyelitis –unspecified cause of encephalitis (323.9; G04.9)  1,648 (28.8) 
Encephalitis, myelitis, and encephalomyelitis –other cause of encephalitis (323.8; G04.8)  260 (4.4) 
*ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ICD-10-AM, International Classification of Diseases, 10th 
Revision, Australian Modification. RESEARCH
cant for pathogens with known etiologies (decline of 1.4% 
per year, p = 0.13, 95% CI 0.4%–3.2%,). This trend did not 
change when adjusted for age groups.
The proportion of cases with pathogens of known eti-
ologies was higher for men than for women; the average 
hospitalization rate for men with encephalitis with a known 
etiology was 1.9/100,000 compared with 1.3/100,000 for 
women with encephalitis with a known etiology. In con-
trast,  rates  for  patients  with  encephalitis  with  unknown 
etiologies were similar for men (3.8/100,000) and women 
(3.4/100,000). When the diagnosis of Toxoplasma enceph-
alitis was excluded, the rate for hospitalizations for men 
with encephalitis with identified etiologies (1.5/100,000) 
was similar to the rate for women (1.3/100,000).
The  proportion  of  hospitalizations  with  encephalitis 
with known etiology varied little among hospitals; a no-
table exception was a large Sydney hospital specializing 
in HIV-related medicine. For this hospital, the higher pro-
portion of patient admissions with encephalitis with known 
etiology (50%) resulted from a high number of Toxoplasma 
encephalitis admissions.
Known Causes
Herpes encephalitis accounted for a relatively stable 
proportion of encephalitis hospitalizations during the study 
period  (Figure  3).  Toxoplasma  encephalitis  hospitaliza-
tions increased early in the study period and peaked in 1993   
(Figure  4).  Few  toxoplasmosis  hospitalizations  occurred 
during the last 10 years of the study period. Subacute scle-
rosing panencephalitis (SSPE) was the only other diagno-
sis that  decreased most years after 1994. These decreases 
appeared to contribute to the overall downward trend in 
hospitalizations with encephalitis with a known etiology, 
although this trend was not statistically significant; SSPE 
hospitalizations declined throughout the 1990s (Figure 5).
Discussion
Despite being uncommon (5.2/100,000 population an-
nually), encephalitis is of public health importance because 
rapid response to cases may prevent additional transmitted 
cases of the underlying etiologies. Currently, nearly 70% of 
encephalitis cases have no identified etiology, so encepha-
litis is presently not amenable to public health prevention 
and control measures. This trend of encephalitis with un-
identified etiology is seen elsewhere in developed coun-
tries and seems to occur even in the presence of extensive 
laboratory testing (22). Because of the number of emerging 
infectious diseases associated with encephalitis in Austra-
lia and elsewhere in recent times, surveillance should be 
enhanced.
The encephalitis hospitalization rate and case-fatali-
ty rate in NSW are lower than estimates from the United 
States (rate of 5.2 vs. 7.3/100,000/year, respectively; case-
fatality rate of 4.6% vs. 7.4%, respectively); however, these 
differences may result in part from differences in study 
methods. The US study included hospitalizations for which 
encephalitis was the primary, secondary, or other discharge 
diagnosis, whereas our study included only those cases for 
which encephalitis was the primary discharge diagnosis. 
Similarly, a study in the United Kingdom found a hospi-
talization rate of 1.5 per 100,000 per year. The UK study 
included only cases of viral encephalitis and thus used a 
smaller number of ICD codes in the data collection than our 
study. This selection could account for the lower number of 
cases, although a true difference cannot be ruled out.
Our findings demonstrated a higher rate of encephalitis 
admissions that had no identified etiology (69.6%) in NSW 
than has been found in either the United States (59.5%) or 
the United Kingdom (60.0%). Although different methods 
of data extraction and different sample sizes may have con-
tributed to these differences, a true difference in pathogens 
causing encephalitis could exist among these 3 countries. 
The high proportion of encephalitis cases with unknown 
etiology across all 3 countries emphasizes the limits of cur-
rent diagnostic tools and/or the lack of systematic inves-
tigation of encephalitis cases. In Australia, the proportion 
of encephalitis deaths with no identified etiology increased 
from 47.0% during 1979–1992 to 57.2% during 1993–2006 
(C. Huppatz, unpub. data). Although the datasets for hos-
pital inpatients and for death registry data are not directly 
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Figure 1. Encephalitis hospitalization rates by year and by known 
and  unknown  pathogen  etiology,  New  South  Wales,  Australia, 
1990–2007.
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  Figure 2. Average rates of encephalitis hospital admissions by 10-
year age groups and by known and unknown pathogen etiology, 
New South Wales, Australia, 1990–2007.Etiology of Encephalitis in Australia, 1990–2007
comparable, this relative increase in deaths from encepha-
litis with unknown etiology further emphasizes the need for 
enhanced routine surveillance.
Our data showed a higher rate of total encephalitis ad-
missions for men (54.3%) compared with women (45.7%); 
this difference is largely due to a higher rate of toxoplasmo-
sis encephalitis hospitalizations for men, a finding similarly 
observed in the US hospitalization data (11). Toxoplasma 
encephalitis is likely associated with HIV infection in the 
early 1990s. 
The proportion of patients with encephalitis with un-
identified etiology did not change during the study period, 
despite innovations in laboratory testing, particularly in-
creased use of PCR testing after its described use for herpes 
encephalitis in 1990 (23). Interestingly, encephalitis with 
unknown etiology was not higher in rural areas, where lack 
of laboratory facilities and access to specialty units may 
constrain diagnosis. We found a similar rate of known to 
unknown etiologies for urban and rural hospitals, with the 
exception of 1 HIV referral center that had a high number 
of toxoplasmosis encephalitis admissions.
Our study showed that the most common known etiol-
ogy was herpes virus (12.9%); encephalitis hospitalization 
rates changed little for patients with this virus during the 
study period, a finding consistent with the US and UK stud-
ies (11,17).
A decrease in encephalitis admissions due to Toxo-
plasma  sp.  was  observed  after  a  peak  occurred  for  this 
pathogen in 1993. This decline in toxoplasmosis can be 
explained by the increasing use of prophylactic treatment 
for Toxoplasma gondii infection in people with HIV infec-
tion, a recommendation first widely published in Australia 
in 1994 (24).
The decrease in SSPE, a neurodegenerative disorder 
caused by the persistence of measles virus in the central 
nervous system (25), reflects the success of immunization 
in Australia. The median incubation period for the develop-
ment of SSPE after measles infection is 6–8 years (25). Our 
data show a decline in SSPE admissions after this illness 
peaked in 1991. This decline most likely resulted from a 
national measles vaccination campaign in Australia in 1987 
(26). The surprising increase of SSPE in 2005 can be partly 
explained by 3 admissions of 1 patient with SSPE. This 
patient’s recurring hospitalizations were identified during a 
detailed review of encephalitis patients at the John Hunter 
Hospital, NSW, Australia (C. Huppatz, unpub. data). The 
decline in SSPE diagnoses builds on the growing evidence 
of the success of vaccination in decreasing illness and death 
from measles and its complications (26,27).
Several limitations are associated with use of hospi-
tal coding data to estimate the impact of disease. During 
the  study  period,  the  ICD  coding  system  changed,  and 
ICD-10  (1998–2007)  contained  several  new  codes  not 
present in ICD-9 (1990–1997), including codes for zoster 
encephalitis, listeria meningoencephalitis, and enteroviral 
encephalitis. Before 1998, ICD-9 codes must have been 
designated to conditions associated with the new ICD-10 
codes; however, which codes were used cannot definitely 
be  determined.  Fortunately,  hospitalizations  coded  with 
the unknown ICD-9 codes account for a small proportion 
(<6%) of all encephalitis cases reported (Table).
In addition to limitations due to the ICD coding chang-
es, differences may exist in diagnostic criteria for encepha-
litis used by clinicians and in inconsistencies among hos-
pitals regarding coding practices and hospital admission 
criteria. Our data represent hospital admissions, rather than 
cases of encephalitis. Although this study criterion is useful 
for estimating the impact of disease as it relates to hospital 
service provision, case-fatality rates will be underestimated 
by the use of hospital admission data, rather than true cas-
es, as some patients had multiple hospital admissions. The 
proportion of encephalitis cases with known and unknown 
etiologies remained constant, despite the ICD coding sys-
tem change.
A previous study undertaken in the Northern Terri-
tory of Australia also found a high proportion (53%) of en-
cephalitis cases with unknown etiologies (21). The North-
ern Territory has a distinctly different climate from that of 
NSW, and geographic variation exists in cases of encepha-
litis with known etiologies. For example, Murray Valley 
encephalitis and Kunjin encephalitis occur predominantly 
in the north. The relatively high proportion of encephali-
tis infections with unknown etiology appears consistent in 
these 2 different Australian regions.
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Figure 3. Herpes encephalitis hospitalizations by year, New South 
Wales, Australia, 1990–2007.
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Figure 4. Toxoplasma encephalitis hospitalizations by year, New 
South Wales, Australia, 1990–2007.RESEARCH
Conclusions
Acute encephalitis has heralded the emergence of mul-
tiple virulent pathogens (28), including West Nile virus, 
Hendra virus, Nipah virus, Murray Valley encephalitis vi-
rus, and Japanese encephalitis virus, all of which can cause 
severe illness and death (2,4,29–31). Although emerging 
infectious diseases may become apparent due to large out-
breaks in humans, such as the Nipah virus outbreak in Ma-
laysia (4), the diseases that emerged recently in Australia 
(e.g., Hendra virus infection and Australian bat lyssavirus 
infection ) have been found in only a few persons (2,32). 
Consistent with US and UK studies (11,17), we found a 
high proportion (70%) of encephalitis cases with an un-
known etiology in NSW. This finding highlights the need 
to monitor trends in encephalitis illness in Australia and 
to improve identification of the etiologies of encephalitis 
for detection of emerging infectious diseases. Based on our 
findings, we recommend that in Australia, surveillance be 
considered for encephalitis to assist in pathogen identifica-
tion, alert authorities to outbreaks, and allow timely public 
health action.
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